Sprott Physical Platinum and Palladium Trust Updates Its “At-the-Market” Equity Program

(TSX:SPPP),(NYSE:SPPP),(TSX:SPPP-U), TORONTO, Sept. 09, 2025 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Platinum and Palladium Trust (NYSE: SPPP) (TSX: SPPP / SPPP.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical […]

Sprott Physical Platinum and Palladium Trust Updates Its “At-the-Market” Equity Program

Sprott Physical Platinum and Palladium Trust Updates Its “At-the-Market” Equity Program GlobeNewswire September 09, 2025 TORONTO, Sept. 09, 2025 (GLOBE NEWSWIRE) — Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Platinum and Palladium Trust (NYSE: SPPP) (TSX: SPPP / SPPP.U) (the “Trust”), a closed-ended mutual

Sutter Health Named Among Top 5 Best Workplaces for Innovators by Fast Company

San Francisco, Sept. 09, 2025 (GLOBE NEWSWIRE) — Sutter Health has been recognized by Fast Company as one of America's Best Workplaces for Innovators in 2025. Sutter ranked fourth on the list of just 100 top businesses and organizations that empower their workforce to harness innovation to tackle big challenges and advance bold new ideas.

Sutter Health Named Among Top 5 Best Workplaces for Innovators by Fast Company

Sutter Health Named Among Top 5 Best Workplaces for Innovators by Fast Company GlobeNewswire September 09, 2025 San Francisco, Sept. 09, 2025 (GLOBE NEWSWIRE) — Sutter Health has been recognized by Fast Company as one of America's Best Workplaces for Innovators in 2025. Sutter ranked fourth on the list of just 100 top businesses and

Analog Pharma Canada launches its first product on the Canadian market

This launch will expand the reach of a unique Canadian expertise in maternal health to serve generations to come. Analog Pharma Canada, a pharmaceutical company specializing in generics for rare and ultra-rare diseases, as well as generic versions of Duchesnay-owned products, and member of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation

Emergent BioSolutions Receives New Contract Modification for ACAM2000(R), (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

(NYSE:EBS), GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000(R), (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales

Donald Trump Jr. Joins Mixed Martial Arts Group (MMA.INC) as Strategic Advisor

(NYSE MKT:MMA), Highlights Mr. Trump Jr. to serve alongside Conor McGregor, MMA.INC's most prominent investor, as Strategic Advisor to MMA.INC He brings invaluable technology and media expertise as Director of Trump Media and Technology Group, operator of Truth Social and as Co-Founder of World Liberty Financial As a business, media, and global brand building powerhouse,

Colliers elevates U.S. multifamily presence

(NASDAQ:CIGI),(TSX:CIGI), TORONTO and DALLAS, Sept. 09, 2025 (GLOBE NEWSWIRE) — Leading diversified professional services and investment management firm Colliers (NASDAQ and TSX: CIGI) today announced the acquisition of Greystone Sales Group, LLC (“GREA Dallas”). Details of the transaction were not disclosed. GREA Dallas is a prominent multifamily investment sales firm in Texas. The firm's 25

Independent Proxy Advisor ISS Recommends Shareholders Vote FOR DallasNews’ Merger with Hearst

(NASDAQ:DALN), ISS Agrees that Hearst Merger Delivers Certain and Immediate Value for Shareholders at a “Triple-Digit Premium” ISS in Agreement with Glass, Lewis & Co. Recommendation to Vote FOR the Hearst Merger DallasNews Board Reiterates Recommendation that Shareholders Vote FOR the Hearst Merger to Secure a Certain and Substantial Premium DALLAS, Sept. 09, 2025 (GLOBE

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead

(NASDAQ:XLO), Phase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027 WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people

Scroll to Top